[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gestational-diabetes-mellitus-in-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gestational-diabetes-mellitus-in-pregnancy":424},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,52,96,108,153,178,197,225,255,280,303,329,356,376,403],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100053733",false,"NCT07551011","Impact of Behavioural Modification Working Toolkit Among Women With Gestational Diabetes Mellitus and Hypertension","Impact of Behavioural Modification Working Toolkit Among Women With Gestational Diabetes Mellitus and Hypertension: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant women aged 15-49 years.\n* Gestational age between 16 and 20 weeks at enrolment.\n* Diagnosed with both gestational diabetes mellitus (GDM) and pregnancy-induced hypertension (PIH).\n* At least one prior antenatal visit at the study site.\n\nExclusion Criteria:\n\n* Pre-existing diabetes mellitus or chronic hypertension prior to pregnancy.\n* Pre-existing renal disease, thyroid disease, or major hematological disorders.\n* Multiple pregnancy (e.g., twins, triplets).\n* Severe psychiatric illness.","FEMALE","15 Years","49 Years",{"count":19,"type":20},220,"ESTIMATED","INTERVENTIONAL",[23],"NA","This trial aims to evaluate the effectiveness of a Behavioral Modification Working (BMW) Toolkit in improving glycemic control and blood pressure among pregnant women diagnosed with both GDM and PIH.",[26,27],"Gestational Diabetes Mellitus in Pregnancy","Hypertension ,Pregnancy",[29,30,31,32,33,34,35,36,37,38],"Gestational Diabetes Mellitus","Pregnancy Induced Hypertension","Maternal health","Childbirth","Risk Factors","intervention","BMW Toolkit","Dietary habits","Physical activity","sleep pattern","RECRUITING","2026-07-09",{"date":42,"type":43},"2026-07-13","ACTUAL",{"date":45,"type":43},"2026-04-21",{"date":47,"type":20},"2027-01-15",{"name":49,"class":50},"University of the Punjab","OTHER",2,{"id":53,"slug":4,"hasResults":10,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":10,"sex":15,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":63,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":78,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100636441","NCT07565727","Cardiometabolic Disease and Substrate Metabolism","Cardiometabolic Disease, Substrate Metabolism, and Abnormal Placental Pathology: a Multimodal Maternal-Fetal Study","CAP","Inclusion Criteria:\n\n* Age 18-45\n* Any pre-pregnancy BMI\n* At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines\n* Willingness to adhere to aspirin therapy\n* Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n* Gestational age at enrollment \\\u003C18 weeks\n* Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n* Type 1 Diabetes Mellitus\n* Current gestational diabetes mellitus\n* Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n* Thrombophilia\n* Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n* Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n* Current or recent use of steroids\n* Current use of prophylactic or therapeutic anticoagulation\n* Medical contraindication to aspirin therapy\n* Molar pregnancy\n* Renal disease\n* Inability or unwillingness to give informed consent\n* Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators","18 Years","45 Years",{"count":62,"type":20},50,"9 Months","OBSERVATIONAL","This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.",[67,68,69,70,71,26,72,73,74,75,76,77],"Preeclampsia","Gestational Diabetes Mellitus (GDM)","Preeclampsia (PE)","Preeclampsia (PE) Risk","Gestational Diabetes","Cardiometabolic Diseases","Insulin Resistance","Placental Dysfunction","Pregnancy","Pregnancy Complications","Gestational Complications",[79,80,67,71,81,82,83,84,85],"Cardiometabolic disease","Substrate metabolism","Insulin resistance","HOMA-IR","Lipid oxidation","Placental dysfunction","Chorangiosis","2026-04-27",{"date":88,"type":43},"2026-05-04",{"date":90,"type":43},"2025-12-10",{"date":92,"type":20},"2027-08",{"name":94,"class":50},"University of Tennessee Graduate School of Medicine",1,{"id":97,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":24,"conditions":100,"keywords":101,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":107,"locationsCount":51},"100635309",{"count":19,"type":20},[23],[26,27],[29,30,31,32,33,34,35,36,37,38],"2026-04-24",{"date":104,"type":43},"2026-04-30",{"date":45,"type":20},{"date":47,"type":20},{"name":49,"class":50},{"id":109,"slug":4,"hasResults":10,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":15,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":21,"phases":119,"briefSummary":120,"conditions":121,"keywords":137,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":95},"100634052","NCT07534670","Early Pregnancy Lifestyle and Glucose Patterns: A Substudy of TOFFFY","Early-Pregnancy Chronobehavioural Profiles and Continuous Glucose Dynamics: A Nested Randomised Pilot Study of TOFFFY","Inclusion Criteria:\n\n* Enrolled in the Towards Optimal Fertility, Fathering and Fatherhood studY (TOFFFY) (NCT06293235)\n* Females who are currently pregnant and with viable intrauterine pregnancy at ≤13 weeks gestation at enrolment\n\nExclusion Criteria:\n\n* Females with pre-existing diabetes mellitus (Type 1 or Type 2) and\u002For chronic medical conditions affecting glucose metabolism\n* Females who are taking medications known to significantly affect glucose metabolism\n* Females with multiple pregnancy (e.g., twins or higher-order gestation)\n* Females who are unable to comply with study procedures, including: Inability to use smartphone-based applications and inability to wear wrist actigraphy device",true,"21 Years","39 Years",{"count":118,"type":20},140,[23],"The goal of this clinical trial is to examine how daily behavioral patterns in early pregnancy, including sleep, physical activity, and meal timing, influence continuous glucose dynamics and subsequent risk of gestational diabetes mellitus (GDM) in pregnant women without pre-existing diabetes.\n\nThe main questions it aims to answer are:\n\n1. Do early-pregnancy chronobehavioral patterns (e.g., irregular sleep, night eating, and unstable rest-activity rhythms) relate to continuous glucose patterns measured using continuous glucose monitoring (CGM)?\n2. Can early behavioral and CGM-derived measures predict glucose regulation and metabolic outcomes later in pregnancy (24-28 weeks)?\n3. Does real-time self-monitoring using wearable devices and food logging improve glycemic outcomes compared to usual care?\n\nThis study is a prospective, nested randomized pilot trial embedded within the ongoing Towards Optimal Fertility, Fathering and Fatherhood studY (TOFFFY) cohort (NCT06293235) at KK Women's and Children's Hospital, Singapore. A total of 140 pregnant women without pre-existing diabetes, recruited at ≤13 weeks gestation, will be randomized in a 1:1 ratio to either a pilot arm (wearable-based self-monitoring) or a control arm (usual care).\n\nParticipants in the pilot arm (n=70) will undergo intensive behavioral and metabolic monitoring over a 14-day period in early pregnancy, including continuous glucose monitoring using a CGM device, wrist actigraphy to assess sleep-wake and rest-activity patterns, and an AI-supported mobile application to record meal timing and dietary intake. Participants will have real-time access to their glucose data and behavioral feedback, enabling self-monitoring and potential behavioral adjustments.",[122,123,124,125,126,75,127,26,128,129,130,131,132,133,134,135,136],"Continuous Glucose Monitoring","Diabetes, Gestational","Diet During Pregnancy","Meal Time","Actigraphy","Glucose Intolerance During Pregnancy","Circadian Rhythm","Sleep","Chronobiology","Wearable Electronic Devices","Mobile Applications","Blood Glucose Profile","Metabolic Diseases","Randomized Controlled Trial","Pilot Study",[138,139,140,141,31,142],"Risk factor","Lifestyle","Early pregnancy","Chrono-disruptive behaviours","Lifestyle intervention","NOT_YET_RECRUITING","2026-04-22",{"date":86,"type":43},{"date":147,"type":20},"2026-05-01",{"date":149,"type":20},"2027-06-30",{"name":151,"class":152},"KK Women's and Children's Hospital","OTHER_GOV",{"id":154,"slug":4,"hasResults":10,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":10,"sex":15,"minAge":59,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":95},"100469118","NCT05388643","Early Detection of Gestational Diabetes Mellitus in Pregnancy","Early Detection of Gestational Diabetes Mellitus in Pregnancy: A Randomized Trial","Inclusion Criteria:\n\n* 1\\) age greater than or equal to 18 years old,\n* 2\\) singleton gestation less than or equal to 12 weeks at initial obstetric visit,\n* 3\\) receiving prenatal care at UMMHC and plans to deliver at UMMHC,\n* 4\\) able and willing to provide informed consent,\n* 5\\) English or Spanish speaking, and\n* 6\\) are at high risk for developing GDM by ACOG clinical risk factor guidelines.\n\nExclusion Criteria:\n\n* 1\\) known diagnosis of pre-existing pregestational diabetes,\n* 2\\) plan to receive prenatal care or deliver outside of UMMHC,\n* 3\\) inability to complete oral glucose tolerance test (e.g. gastric bypass surgery history, gastric dumping syndrome history, vomiting of oral glucose tolerance test), or\n* 4\\) systemic steroid use.",{"count":160,"type":20},80,[23],"The purpose of this study is to develop an implementation protocol and test the feasibility and acceptability of a first trimester screening protocol for the early detection of gestational diabetes mellitus (GDM).",[26,164],"Pregnancy, High Risk",[75,71,166,167,168],"Screening","Maternal Outcomes","Neonatal Outcomes","2026-03-31",{"date":171,"type":43},"2026-04-06",{"date":173,"type":43},"2025-07-01",{"date":175,"type":20},"2026-12-01",{"name":177,"class":50},"University of Massachusetts, Worcester",{"id":179,"slug":4,"hasResults":10,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":10,"sex":15,"minAge":59,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":95},"100627469","NCT07449039","Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial","POSTPOD","Inclusion Criteria:\n\n* Prenatal care at UCLA Health\n* Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica\n* Confirmed gestational diabetes diagnosis based on 2-step approach\n* Maternal age \\>= 18 years\n\nExclusion Criteria:\n\n* Pre-gestational diabetes (T1DM or T2DM)\n* Multifetal gestation\n* Intra-amniotic infection by clinical criteria\n* Postpartum hemorrhage\n* Maternal ICU admission\n* Known allergy to medical-grade adhesive\n* Presence of skin lesions at anticipated CGM application site\n* Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial\n* Metformin use\n* Steroid use\n* Terbutaline use within 4 hours of delivery\n* Cystic fibrosis\n* MODY (mature onset of diabetes in the young)",{"count":62,"type":20},[23],"This is a pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) within hours of delivery to predict long-term risk of Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes.\n\nParticipants will be provided a CGM within 2 hours after delivery and wear the device for 24 hours. Participants will be instructed to peel off the device after 24 hours. Participants will also be asked to complete two surveys regarding their experience at 1-3 months postpartum and 12-14 months postpartum.",[26],"2026-02-26",{"date":190,"type":43},"2026-03-04",{"date":192,"type":43},"2025-09-28",{"date":194,"type":20},"2030-06",{"name":196,"class":50},"University of California, Los Angeles",{"id":198,"slug":4,"hasResults":10,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":114,"sex":15,"minAge":59,"maxAge":60,"enrollmentInfo":203,"targetDuration":4,"studyType":21,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":95},"100558262","NCT06548828","Effects of a Non-nutritive Sweetener Reduction Intervention in Pregnancy and Lactation on Maternal and Infant Outcomes","Effects of a Non-nutritive Sweetener Reduction Intervention in Pregnancy and Lactation on Maternal and Infant Outcomes (the SweetPea Trial)","Inclusion Criteria:\n\n* Pregnant\n* ≤ 16 weeks gestation\n* Singleton pregnancy\n* Report frequent NNS beverage consumption (≥ 7 servings\u002Fweek)\n* 18-45 years of age\n* Able to read English at a 5th grade level; and\n* Intend to breastfeed for at least the first 6 months of life.\n* For infants: The mother must be enrolled and provide assent for the infant to participate.\n\nExclusion Criteria:\n\n* Physical or mental concerns preventing study participation;\n* Medication (e.g., metformin; GLP-1 agonists) use that may affect body weight, body composition, insulin resistance, or lipid profiles;\n* Tobacco or drug use during pregnancy;\n* Alcohol consumption (\\>1 drink per week) during pregnancy;\n* Pre-existing gastrointestinal, inflammatory, or malabsorptive disorders (e.g., - Crohn's disease, ulcerative colitis, inflammatory bowel disease) that may impact NNS absorption or gut microbiota;\n* Known suspected\u002Fconfirmed genetic fetal abnormalities or suspected or known congenital birth defects.\n* History of prior gastric bypass surgery.",{"count":204,"type":20},324,[23],"The effects of consuming non-nutritive sweeteners (NNS) during pregnancy and lactation on infant obesity and cardiometabolic disease risk are not well understood. In this project, pregnant women who frequently consume NNS will be randomly assigned to an NNS-restriction intervention (NNS restriction during pregnancy and lactation or during lactation only) or a control group (no NNS restriction) to determine whether NNS consumption during pregnancy and\u002For lactation affects infant body composition, maternal blood sugar during pregnancy, and the infants' gut microbiome and metabolome. The results of this study have the potential to shape recommendations around NNS consumption during pregnancy and lactation, thereby potentially improving maternal and infant metabolic health and reducing the global burden of obesity and cardiometabolic disease.",[26,127,208],"Non-nutritive Sweeteners Consumption in Pregnancy and\u002For Lactation",[210,75,211,212,213,214,215],"Non-nutritive sweeteners (NNS)","Lactation","Infant fat mass","Gestational diabetes (GDM)","Glucose tolerance","PeaPod","2026-02-16",{"date":218,"type":43},"2026-02-18",{"date":220,"type":43},"2024-08-19",{"date":222,"type":20},"2029-02-01",{"name":224,"class":50},"George Washington University",{"id":226,"slug":4,"hasResults":10,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":10,"sex":231,"minAge":59,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":21,"phases":235,"briefSummary":236,"conditions":237,"keywords":239,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":95},"100519819","NCT06048510","New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.","GLYCAGEST","Inclusion criteria:\n\n1. Age ≥ 18 years\n2. Singleton pregnancy (or twin pregnancy reduced spontaneously or medically before 14 weeks of amenorrhea)\n3. Gestational age at inclusion \\\u003C28 weeks of amenorrhea\n4. Participant affiliated with or beneficiary of a social security scheme\n5. Collection of patient consent.\n\nExclusion criteria:\n\n1. Gestational age at inclusion ≥ 28 weeks of amenorrhea\n2. Multiple pregnancy\n3. Known diabetes prior to pregnancy\n4. History of bariatric surgery\n5. Expected delivery in another maternity unit not participating in the study\n6. Person deprived of liberty by judicial or administrative decision\n7. Guardianship or curatorship\n8. Participant not affiliated or not benefiting from a social security scheme.","ALL","99 Years",{"count":234,"type":20},800,[23],"Gestational diabetes mellitus (GDM) increases the risk of macrosomia and other adverse pregnancy outcomes. Screening strategies are debated: universal vs. selective, and macrosomia may begin before the time of screening, suggesting that glycation markers may have an interest. The objective of this trail is to compare novel markers: skin autofluorescence and glycated albumin, to HbA1c (reference) as predictors of GDM, macrosomia and other adverse outcomes, in pregnant women.",[238,26],"Macrosomia, Fetal",[240,241,242,243,244,245],"skin autofluorescence","glycated albumin,","HbA1c","glycation biomarkers","macrosomia","gestational diabetes mellitus","2026-01-13",{"date":248,"type":43},"2026-01-15",{"date":250,"type":43},"2023-12-18",{"date":252,"type":20},"2028-09",{"name":254,"class":50},"University Hospital, Bordeaux",{"id":256,"slug":4,"hasResults":10,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":114,"sex":15,"minAge":59,"maxAge":60,"enrollmentInfo":261,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":265,"conditions":266,"keywords":269,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":95},"100589008","NCT06948825","Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes","GooDMomS2","Inclusion Criteria:\n\n* Mothers between 8 weeks and 12 months postpartum from a pregnancy complicated by GDM will be recruited. The research team will begin recruiting women who are at least 8 weeks postpartum to provide time to describe the study and answer any questions. Mothers who want to participate will be enrolled in the study between 12 weeks and 12 months postpartum.\n* BMI of 25 kg\u002Fm2 to 45 kg\u002Fm2\n* Singleton delivery\n* Participants must also have a working cell phone, be willing to accept email or text messages attend Zoom calls, and be willing to be potentially randomized to drug therapy with Metformin.\n\nExclusion Criteria:\n\n* Pregnant or planned pregnancy within the next 6 months.\n* Participation in any other weight loss program or taking weight loss medication.\n* Normal or underweight BMI (BMI \\\u003C 24.9 kg\u002Fm2)\n* Multi-fetal (twins or triplets) gestation\n* Women with type 1 or type 2 diabetes, malignancy, other serious co-morbidities (advanced kidney disease, NYHA class 3-4 CHF, advanced COPD), schizophrenia or other major psychiatric disease, and substance abuse or AIDS.\n* Women whose infants have significant medical conditions, such as congenital heart disease, renal impairment, or hepatic impairment.",{"count":262,"type":20},60,[264],"PHASE2","The goal of this clinical trial is to evaluate the effectiveness of a 6-month lifestyle intervention compared to Metformin in postpartum women who have delivered a singleton, live born infant within the last 12 weeks to 1 year and had a pregnancy complicated by gestational diabetes. The main question this study aims to answer is:\n\nIs a Lifestyle Intervention or Metformin more effective for weight loss in postpartum women with recent gestational diabetes?\n\nResearchers will compare a 6-month Lifestyle Intervention and Metformin to see if either intervention is more effective in achieving weight loss and improving health outcomes.\n\nParticipants will:\n\n* Attend an in-person baseline visit to receive a Bluetooth-enabled scale and Fitbit, have blood drawn for testing, and have their height, weight, and blood pressure measured. Participants will also be asked to bring in their infant, and the study team will measure the infant's weight and length.\n* Track diet, physical activity, and weight using the Fitbit and Looseit! apps.\n* Attend weekly online group sessions for the first 4 weeks, then biweekly sessions.\n* If not meeting weight loss goals, be randomized to either Enhanced Lifestyle Intervention or Metformin arms of the study.\n* If randomized to Metformin, participants will attend one in-person meeting with the study provider, get blood drawn for testing, and undergo a urine pregnancy test before starting the medication.\n* Continue with biweekly group sessions or have regular check-in calls.\n* If randomized to the Enhanced Lifestyle Intervention, participants will get a free Instacart membership, a 1:1 session with the study health counselor focused on meal planning and free grocery delivery once a week for the remainder of the study.\n* Participants will meet every other week via Zoom with the health counselor and other participants in the enhanced lifestyle arm.\n* At the end of the 6 months, all participants will come for an in-person visit to get blood drawn for testing. Participants will also be asked to bring in their infant, and the study team will measure the infant's weight and length.",[267,26,268],"Weight Loss","Postpartum Care",[270,271,272],"diabetes prevention","gestational diabetes","lifestyle intervention","2026-01-12",{"date":246,"type":43},{"date":276,"type":43},"2025-10-27",{"date":278,"type":20},"2026-11",{"name":224,"class":50},{"id":281,"slug":4,"hasResults":10,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":114,"sex":15,"minAge":59,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":287,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":302},"100589639","NCT06957028","CGM for the Early Detection and Management of Hyperglycemia in Pregnancy","Inclusion Criteria\n\n1. Maternal age of 18 years and older\n2. Singleton pregnancy\n3. Gestational age up to 14w 6d of pregnancy, determined on ultrasound, for initiation of screening\n\n   • Although it is preferable that ultrasound results be available prior to enrollment, if ultrasound results are not available at the time of enrollment, participant can have CGM initiated but will be dropped if not eligible after results are available\n4. HbA1c \\\u003C6.5% (48 mmol\u002Fmol) since onset of pregnancy\n\n   • If HbA1c result not available at time of enrollment, participant can have blinded screening CGM initiated, but results will be needed prior to randomization to verify eligibility.\n5. No prior history of gestational diabetes mellitus (GDM)\n6. Able to read English or Spanish\n\nExclusion Criteria\n\n1. Signs of abnormal fetal or placental development (suspected fetal anomaly or placenta accreta spectrum, low PAPPA) at first routine prenatal visit\u002Fultrasound\n2. Planned termination of pregnancy or any indications of miscarriage\n3. Prior gastric bypass surgery\n4. Pregravid diabetes (type 1 or type 2)\n5. Unwillingness\u002Finability to wear CGM sensor\n6. Unwillingness to attend routine antenatal obstetric appointments\n7. Use of corticosteroids by a route that can produce hyperglycemia (e.g., oral, intravenous, intramuscular, intra-articular) during the 7 days prior to initiating CGM screening or during the CGM screening\n\n   • Topical and inhaled corticosteroids are acceptable\n8. Use of insulin during the pregnancy prior to enrollment\n9. Use of metformin within one week of the initiation of the blinded CGM sensor for screening or use of a GLP-1 or other weight-reduction medication that can affect glucose levels within 4 weeks of the initiation of the blinded CGM sensor for screening\n10. Deemed unable to participate for medical reasons identified by their physician\n\nAdditional Criteria for RCT Eligibility\n\n1. Screening CGM meeting study criteria for hyperglycemia: 5% to \\\u003C25% time \\>140 mg\u002FdL\n2. Randomization by 16 week 6 days of pregnancy\n3. No participation in a separate intervention trial.",{"count":286,"type":20},6000,[23],"The goal of this clinical trial is to use continuous glucose monitoring (CGM) to quickly detect and manage high blood sugar in pregnant women, early in pregnancy. The main questions it aims to answer are:\n\n(1) any problems for the baby, such as being too large for their age, shoulder injuries (like broken bones), high bilirubin levels needing light treatment, low blood sugar, or needing to stay in the NICU; (2) any high blood pressure issues for the mother during pregnancy.",[26],[291,292,75],"GDM","CGM","2025-12-16",{"date":295,"type":43},"2025-12-23",{"date":297,"type":43},"2025-05-27",{"date":299,"type":20},"2027-11-27",{"name":301,"class":50},"Jaeb Center for Health Research",10,{"id":304,"slug":4,"hasResults":10,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":10,"sex":15,"minAge":59,"maxAge":60,"enrollmentInfo":309,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":95},"100577789","NCT06802861","Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia","RAMP","Inclusion Criteria:\n\n* Recommended aspirin for pre-eclampsia prevention by OB\u002FGYN or MFM specialist based on ACOG and USPSTF guidelines (1 high risk factor, 2+ moderate risk factors)\n\n  * Willingness to adhere to aspirin therapy\n  * Willingness to undergo 2h OGTT for serum and urine collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n  * Gestational age at enrollment \\\u003C16 weeks\n  * Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n\n  * Type 1 Diabetes Mellitus\n  * Current gestational diabetes mellitus\n  * Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n  * Thrombophilia\n  * Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n  * Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n  * Current or recent use of steroids\n  * Current use of prophylactic or therapeutic anticoagulation\n  * Medical contraindication to aspirin therapy\n  * Molar pregnancy\n  * Renal disease\n  * Inability or unwillingness to give informed consent\n  * Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators",{"count":62,"type":20},"This study's primary purpose is to determine the relationship between aspirin metabolism and markers of metabolic dysfunction among patients at risk for preeclampsia.",[67,69,70,312,75,76,71,26,77],"Obesity and Obesity-related Medical Conditions",[314,271,315,316,317,318,291,319,320],"metabolic dysfunction","pregnancy","maternal obesity","maternal insulin resistance","aspirin metabolism","substrate oxidation","gestational glucose intolerance","2025-09-03",{"date":323,"type":43},"2025-09-10",{"date":325,"type":43},"2025-01-01",{"date":327,"type":20},"2028-12-31",{"name":94,"class":50},{"id":330,"slug":4,"hasResults":10,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":114,"sex":15,"minAge":59,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":21,"phases":338,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":95},"100590704","NCT06970886","Effects of Rhythm-Based Music on Pregnancies With Gestational Diabetes","Effects of Rhythm-Based Music on Anxiety, Glucose, and Cortisol in Pregnancies With Gestational Diabetes","Inclusion Criteria:\n\n* Voluntarily agree to participate in the study with informed written consent\n* Diagnosed with Gestational Diabetes Mellitus (GDM) and currently hospitalised\n* In the third trimester of pregnancy\n* Over the age of 18\n* Have a live, single fetus\n\nExclusion Criteria:\n\n* Any condition preventing participation in rhythm-based music making and listening (e.g., hearing, vision, or speech impairments)\n* Regular and routine music listening habits during pregnancy\n* Physical limitations or restrictions\n* Mental or cognitive disorders requiring medication\n* Use of corticosteroids or medications containing corticosteroids\n* Known fetal abnormalities\n* Systemic diseases other than GDM (e.g., Hypertension, Type 1 or Type 2 Diabetes, Thyroid disorders, etc.)\n* Body mass index (BMI) of 30 or higher\n* Discharge from the hospital before the 3rd day of the intervention","35 Years",{"count":337,"type":20},180,[23],"This study is for people who have gestational diabetes, a type of diabetes that happens during pregnancy. People with gestational diabetes may feel more anxious than others during pregnancy. This anxiety can affect their health and their baby's health.\n\nThe goal of this study is to see if rhythm-based music can help lower anxiety and improve blood sugar and stress hormone levels. Music may be a safe and low-cost way to support emotional and physical health during pregnancy.\n\nResearchers will test two types of music activities:\n\nListening to rhythm-based music\n\nDoing rhythm-based music and breathing exercises\n\nThe study will include 180 pregnant participants. They will be randomly placed into one of three groups. Each group will be at a different hospital to prevent crossover. Two groups will receive music activities, and the third group will receive usual care.\n\nParticipants will stay in the hospital for 3 days. During that time:\n\nAnxiety will be measured on day 1 and day 3 using a short questionnaire\n\nBlood sugar will be measured 3 times a day (morning, afternoon, evening)\n\nSaliva samples will be collected on day 3 to measure cortisol (a stress hormone)\n\nResearchers will also record any medications used by participants.\n\nThis study may show that music helps lower anxiety and improve health for people with gestational diabetes. It may also support the use of music as a helpful, non-drug option during pregnancy.",[26,341,342],"Anxiety","Blood Sugar; High",[341,344,345,346],"Blood glucose","Gestational diabetes","Salivary cortisol","2025-05-18",{"date":349,"type":43},"2025-05-22",{"date":351,"type":20},"2025-09-01",{"date":353,"type":20},"2027-04-25",{"name":355,"class":50},"Esin Ceber Turfan, Professor",{"id":357,"slug":4,"hasResults":10,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":10,"sex":15,"minAge":59,"maxAge":4,"enrollmentInfo":362,"targetDuration":364,"studyType":64,"phases":4,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":95},"100583329","NCT06874907","First Trimester Prediction of Gestational Diabetes Mellitus by Continuous Glucose Monitoring.","GLUCO-GCM","Inclusion Criteria:\n\n* Maternal age ≥ 18 years\n* Planned antenatal care at the same centre (i.e. not planning to move before delivery).\n* Singleton pregnancy.\n* Informed and written consent.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years;\n* Multiple pregnancy in current pregnancy;\n\n  * Unconscious or very ill; · Serious mental illness;\n  * Learning difficulties;\n  * Not fluent in local language and absence of interpreter;\n  * Severe congenital anomaly on ultrasound;\n  * Pre-existing diabetes mellitus type 1 or 2;\n  * Patients undergoing metformin therapy for infertility.\n  * Significant pre-pregnancy comorbidities that increase risk in pregnancy, for example renal failure, severe liver disease, transplantation, cardiac failure, psychiatric conditions requiring in-patient admission (\\\u003C1 year);\n  * Significant co-morbidity in the current pregnancy, nephropathy (estimated GFR \\\u003C60ml\u002Fmin), other physical or psychological conditions likely to interfere with the conduct of the study and\u002For interpretation of the trial results;\n  * Participating in another intervention study that influences outcomes of this study;\n  * Allergy to adhesive materials;\n  * Allergy to any of the components of the glucose test:",{"count":363,"type":20},1000,"2 Years","Gestational diabetes mellitus (GDM) is the most common complication of pregnancy, with an incidence rate of 10-15% \\[1\\]. Common risk factors for GDM are increased maternal age and weight and as a consequence of women delaying childbirth and increasing incidence of obesity, there is a corresponding increase in the rate of GDM. GDM is associated with an increased risk of maternal and perinatal short and long-term complications . These include macrosomia, shoulder dystocia, neonatal hypoglycaemia, neonatal hyperbilirubinemia, and perinatal mortality. Maternal complications include higher risks of hypertensive disorders, perineal trauma, and caesarean section. Additionally, both the mothers with GDM and their infants have an increased risk of developing type 2 diabetes mellitus and cardiovascular disease later in life .\n\nScreening and diagnosis of GDM is currently based on an oral glucose tolerance (OGTT), which is carried out at 26-28 weeks' gestation. In addition, an OGTT is carried out at 11-13 weeks in women considered to be at increased risk of GDM based on their demographic characteristics and medical history. Screening and diagnosis of GDM is traditionally delayed until the late second or early third trimester of pregnancy with the rationale that the diabetogenic effects of pregnancy increase with gestation and therefore delayed testing would maximize the detection rate.",[26],"2025-03-10",{"date":369,"type":43},"2025-03-13",{"date":371,"type":43},"2025-03-01",{"date":373,"type":20},"2026-07-01",{"name":375,"class":50},"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia",{"id":377,"slug":4,"hasResults":10,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":114,"sex":15,"minAge":59,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":21,"phases":385,"briefSummary":386,"conditions":387,"keywords":389,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":95},"100516551","NCT06005987","Mobile App Logging for Diabetes in Pregnancy","Effect of a Mobile Application on Blood Sugar Testing Compliance in Pregnant Women With Diabetes","Inclusion Criteria:\n\n* 18 years and older\n* Verified intrauterine pregnancy\n* At least 12 weeks gestation\n* Diagnosed with either type 2 diabetes mellitus or gestational diabetes mellitus.\n\nExclusion Criteria:\n\n* Patients with less than 4 weeks anticipated to be remaining in pregnancy\n* Pre-existing use of a continuous glucose monitor or other mobile application for glucose tracking\n* Type 1 diabetes mellitus\n* Non-English speaking patients","100 Years",{"count":384,"type":20},40,[23],"To determine the effect of using a mobile app versus paper logs on compliance and percentage in range blood sugars in monitoring blood sugar in pregnant women with diabetes.",[26,388],"Type 2 Diabetes",[390,391,392,393],"technology in medicine","mobile applications","blood glucose monitoring","diabetes in pregnancy","2025-01-29",{"date":396,"type":43},"2025-01-31",{"date":398,"type":43},"2024-06-01",{"date":400,"type":20},"2027-01-01",{"name":402,"class":50},"Carolyn Zahler-Miller",{"id":404,"slug":4,"hasResults":10,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":10,"sex":15,"minAge":59,"maxAge":409,"enrollmentInfo":410,"targetDuration":4,"studyType":21,"phases":411,"briefSummary":412,"conditions":413,"keywords":414,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":420,"leadSponsor":422,"locationsCount":4},"100561359","NCT06589141","Comparison Between Metformin and Glyburide in the Management of Gestational Diabetes","Comparison Between Metformin and Glyburide in the Management of Gestational Diabetes: a Randomized Controlled Trial (GDM-MERGE Trial)","Inclusion Criteria:\n\n* Pregnant women over 18 years old.\n* Gestational age between 24 - 28 weeks.\n* New diagnosis of gestational diabetes mellitus using a 2-hour glucose tolerance test.\n* Medical therapy is indicated to control blood glucose following the failure of diet and lifestyle changes to solely achieve glycemic control (A2GDM).\n\nExclusion Criteria:\n\nPatients with pre-gestational diabetes.\n\n* First trimester fasting blood glucose ≥105 mg\u002Fdl or HbA1c \\> 6.4%.\n* Major fetal anomalies.\n* Intrauterine growth restriction (IUGR) before 24 weeks.\n* Abnormal renal or liver function.\n* Contraindications to metformin or glyburide.\n* Medical treatment declined by the patient.\n* Direct indication to commence insulin (initial fasting blood glucose \\>= 7 mmol\u002Fl or 126 mg\u002Fdl or \\>= 6 mmol\u002Fl or 108 mg\u002Fdl with macrosomia or polyhydramnios).\n* Significant medical co-morbidities requiring continuous medical treatment in pregnancy.\n* Non-compliance to blood glucose self-monitoring (missing 50% or more of total readings)","40 Years",{"count":337,"type":20},[23],"This study aims to compare the maternal, fetal, and neonatal outcomes associated with the use of metformin versus glyburide for managing gestational diabetes.\n\nThe objective is to assess the safety and effectiveness profiles of both medications as potential alternatives to initiating insulin therapy.",[26],[415],"Metformin and Glyburide","2024-09-05",{"date":418,"type":43},"2024-09-19",{"date":325,"type":20},{"date":421,"type":20},"2026-06-30",{"name":423,"class":50},"Assiut University",""]